尿精眯与血清CA125联合检测诊断卵巢恶性肿瘤的价值

Diagnostic Value of Combined Test of Urinary Spermidine and Serum CA125 for Malignant Ovarian Tumor

探讨尿精眯(SPD)与血清CA125联合检测对卵巢恶性肿瘤的诊断价值。采用聚酰胺薄膜层析法分别测定20名对照组和47例妇科盆腔肿块患者尿SPD水平,同时用化学发光免疫法检测两组患者的血清CA125水平。结果表明,卵巢恶性肿瘤组患者尿SPD和血清CA125水平(679.49±368.39μg/mg肌酐,251.23±172.48U/L)明显高于对照组(218.76±88.35μg/mg,13.96±12.07U/L)和卵巢良性肿瘤组患者(204.62±85.26μg/mg肌酐,25.29±31.63U/L)。两标记物对卵巢恶性肿瘤的灵敏度分别为80.95%和71.43%,若二者联合灵敏度可高达90.48%。尿SPD和血清CA125联合检测可提高卵巢恶性肿瘤的诊断准确率。

To assess the clinical values of urinary spermidine （SPD） and serum CA125 in the diagnosis of malignant ovarian tumor, urinary SPD levels were determined by polyamide thin layer chromatography in 21 patients with malignant ovarian tumors group, 26 patients with benign tumors and 20 healthy control group. The serum CA125 levels in patients were measured by chemiluminescent immunoassy. The results showed that the levels of urinary SPD and serum CA125 in the patients with malignant ovarian tumors group were significantly higher than those in benign and healthy control groups. The sensitivities of SPD and CA125 in the diagnosis of ovarian cancer were 80. 95% and 71.43% respectively. The sensitivity of combined test of SPD and CA125 was up to 90. 48%. Therefore, the combined detection of two markers may improve the diagnostic accuracy of malignant ovarian tumor.